Progression of parkinsonian signs in Parkinson disease

被引:164
|
作者
Louis, ED
Tang, MX
Cote, L
Alfaro, B
Mejia, H
Marder, K
机构
[1] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA
[2] Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY USA
[3] Columbia Univ, Coll Phys & Surg, Dept Biostat, New York, NY USA
关键词
D O I
10.1001/archneur.56.3.334
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Current knowledge about the rate of progression of extrapyramidal signs (EPSs) in Parkinson disease (PD) is derived largely from cross-sectional studies comparing subjects at various stages of illness rather than longitudinal studies in which the subjects were followed up over time. Objective: To longitudinally study the progression of EPSs in PD by quantifying the rate of change of EPSs and by examining each EPS (rigidity, bradykinesia, tremor, and postural instability) separately. Methods: A community based cohort of 237 patients with PD living in Washington Heights-Inwood in Manhattan, NY, was evaluated at baseline and at yearly intervals. The EPSs were rated using the motor portion of the Unified Parkinson's Disease Rating Scale Motor Examination. Analyses of longitudinal data were performed by applying generalized estimating equations to regression analyses. Results: The total EPS score increased at an annual rate of 1.5 points (1.5%), but, among those who died, the total EPS score increased at an annual rate of 3.6 points (3.6%). Bradykinesia, rigidity, and gait and balance subscores worsened at similar annual rates of 2.0% to 3.1%, whereas the tremor subscore did not clearly worsen with time. Patients with a shorter disease duration (less than or equal to 3 years) may have progressed more rapidly than patients with longer disease duration (annual rate of change, 1.9% vs 1.4%, respectively), although this did not leach statistical significance A high total EPS score was independently associated with dementia, low Activities of Daily Living score, and long disease duration at baseline. Conclusions: In this cohort, the progression of EPSs in PD occurred at a rate of 1.5% per year and at twice that rate among those who died. Bradykinesia, rigidity, and gait and balance impairment worsened at similar rates, whereas tremor did not, suggesting that tremor may be relatively independent of these other cardinal manifestations of PD.
引用
收藏
页码:334 / 337
页数:4
相关论文
共 50 条
  • [21] Parkinson's disease (PD) and Alzheimer's disease (AD) pathology and parkinsonian signs among older persons.
    Schneider, JA
    Bienias, JL
    Bengana, C
    Bennett, DA
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1999, 58 (05): : 553 - 553
  • [22] Ubisol-Q halts the progression of parkinsonian neurodegeneration in rodent models of Parkinson's disease
    Weinstock, Shelley B.
    Sandhu, Jagdeep K.
    Sikorska, Marianna
    Pandey, Siyaram
    Cohen, Jerome
    Lanthier, Patricia
    Miller, Harvey
    Beyer, Melissa
    Sodja, Carolyn
    Facecchia, Katie
    Muthukumaran, Krithika
    Laframboise, Alyson
    Smith, Jessica
    Harrison, Kate
    Lopatin, Daniel
    Keshen, Corrine
    FASEB JOURNAL, 2013, 27
  • [23] Dietary antioxidants associated with slower progression of parkinsonian signs in older adults
    Agarwal, Puja
    Wang, Yamin
    Buchman, Aron S.
    Holland, Thomas M.
    Bennett, David A.
    Morris, Martha C.
    NUTRITIONAL NEUROSCIENCE, 2022, 25 (03) : 550 - 557
  • [24] Association Between Metabolic Syndrome and Mild Parkinsonian Signs Progression in the Elderly
    Peng, Zeyan
    Zhou, Rui
    Liu, Dong
    Cui, Min
    Yu, Ke
    Yang, Hai
    Li, Ling
    Liu, Juan
    Chen, Yang
    Hong, Wenjuan
    Huang, Jie
    Wang, Congguo
    Ma, Jingjing
    Zhou, Huadong
    FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
  • [25] Association of parkinsonian signs with substantia nigra neuron density in deceased older men without Parkinson's disease
    Ross, GW
    Petrovitch, H
    Abbott, RD
    Nelson, J
    Tanner, CM
    White, LR
    MOVEMENT DISORDERS, 2004, 19 : S329 - S329
  • [26] Parkinsonian signs and mortality from Alzheimer's disease
    Bennett, DA
    Beckett, LA
    Wilson, RS
    Murray, AM
    Evans, DA
    LANCET, 1998, 351 (9116): : 1631 - 1631
  • [27] Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges
    Schrag, A
    Schelosky, L
    Scholz, U
    Poewe, W
    MOVEMENT DISORDERS, 1999, 14 (02) : 252 - 255
  • [28] Measuring progression of Parkinson's disease cardinal signs in the Phase 2 SPARK study
    Kilambi, K. P.
    Dam, T.
    Edgerton, J.
    Fox, T.
    Khan, S.
    Xiao, J.
    Yang, M.
    Bergethon, P.
    MOVEMENT DISORDERS, 2021, 36 : S180 - S180
  • [29] The majority of dementia patients with the pathological findings of Parkinson's disease at autopsy do not present with Parkinsonian symptoms or signs and are not treated for Parkinson's disease during their course
    Ala, TA
    Yang, KH
    Sung, JH
    Frey, WH
    NEUROLOGY, 1997, 48 (03) : 2039 - 2039
  • [30] Dimensionality of parkinsonian signs in aging and Alzheimer's disease
    Bennett, DA
    Shannon, KM
    Beckett, LA
    Wilson, RS
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 1999, 54 (04): : M191 - M196